Seventeen patients received placebo medication during a 12-week run-in period, followed by four doubleblind study periods of six weeks each, during which time placebo, 80 mg, 160 mg and 320 mg propranolol dosages were administered. Examination of the frequency of angina episodes and nonprophylactic nitroglycerin consumption revealed significant beneficial clinical responses for both the 160 and 320 mg dosages. Exercise testing also demonstrated increased exercise tolerance (320 mg dose) with a shift of the exercise end point from pain to fatigue in seven of 17 patients. The interrelationships between propranolol daily dosage, clinical response assessed by percent reduction in anginal episodes, beta-adrenergic blockade measured by percent reduction in exercise heart rate and serum levels were examined. In general, serum levels of 30 ng/ml, when drawn 90 to 180 minutes following the last oral dose, were required to achieve a 25% or greater reduction in angina frequency. Serum levels above 30 ng/ml were similarly correlated with a 20% or greater reduction in exercise heart rate at equivalent levels of exercise. Detailed examination of different patterns of clinical response with respect to beta-blockade, serum levels and oral doses are presented.
propranolol plasma levels and the degree of betaadrenergic blockade;6-8 however, clinical data were not available. The present multi-dose trial provided the opportunity to examine the interrelationships between oral dosage, clinical response, propranolol serum levels and degree of beta-adrenergic blockade as assessed by exercise testing.
Methods

Clinical Features of Study Patients
Twenty-three patients entered this study; however, two did not proceed beyond initial placebo periods because of insufficient angina in one and development of unstable angina in the other. All 21 patients who received propranolol were men, with an age range of 41-70 years (mean age 55). Three patients were taking oral hypoglycemic drugs for diabetes mellitus, six patients had mild hypertension (five of these were receiving diuretics); seven patients were receiving anticoagulants, and 15 patients smoked cigarettes. The concomitant medications were taken throughout the trial. Sixteen patients had previously used long-acting oral nitrates, which were discontinued at the time of entry into the study. No other changes in medications or dietary intake were made during the course of the study. Coronary artery disease was documented in all patients by prior myocardial infarction (15 patients) , by coronary arteriography (9 patients), or by both. Angina pectoris had been present for one to 19 years, and the severity of symptoms as indexed by the New York Heart Association placed three patients in class II, 11 patients in class III, and seven patients in class IV. Two Circulation, Volume 51, June 1975 patients had mild congestive heart failure and two others had moderate congestive heart failure, all four of whom were controlled with chronic digitalis therapy. Thirteen patients had significantly diminished pulse amplitude in the lower extremities, with three patients having mild claudication and three having moderate claudication.
All patients had a stable level of angina pectoris for three months prior to this trial, were ambulatory outpatients for its duration, and had five or more clearly discernible angina episodes per week. Informed consent for participation in this study was obtained from each subject. Patients were instructed to be as active as their symptoms would allow and to use sublingual nitroglycerin tablets for the relief of angina episodes. Prophylactic nitroglycerin was used infrequently by four of the study patients, and this consumption was recorded.
Single-Blind Run-In Period All patients initially entered a single-blind placebo run-in period of 12 weeks' duration. Four six-week study periods were then utilized to determine the effects of the drug. Every six weeks (during both run-in and study periods) a new dose was initiated with one tablet daily, which was increased by one tablet every other day until a dose of one tablet four times daily was reached. Patients were seen every two weeks for history and physical examination. At each visit, a new medication bottle was provided and the tablets remaining in the previous bottle were counted. Patients were asked to keep a written record of each angina attack in a small printed diary. This booklet was collected every two weeks and a new one supplied. At the conclusion of each two-week period, the patient summarized his impressions of the severity, frequency, and response of the angina to nitroglycerin. At the end of each six-week dose period, electrocardiogram, chest X-ray, hematologic and biochemical determinations were monitored. Treadmill exercise testing was performed on three separate occasions during the run-in period.
Eleven of the 21 patients completing the single-blind period had previously participated in a study of practolol efficacy for the treatment of angina.9 These 11 patients had already participated in an identical 12-week single-blind placebo run-in period and moved directly from the last double-blind practolol dose period into the first six-week dose period of the double-blind propranolol protocol. These patients had stable angina and no more than 12 weeks elapsed from the completion of their single-blind run-in period until their initial double-blind propranolol period. Their clinical features and responses to propranolol were not different from those observed for the rest of the patients.
Double-Blind Periods
Following the 12-week single-blind run-in period, patients entered the double-blind portion of the study only if they had five or more angina episodes per week. Patients were started on a new dose of medication every six weeks in the same manner as during the run-in period. The same observations of efficacy and safety parameters were made at two-week intervals and at the end of the sixth week, as in the single-blind periods. Placebo and three dose levels of propranolol (80, 160 and 320 mg/day) were examined in four sequential six-week double-blind periods (table 1). The order of drug administration was selected by randomizing a Latin square. Patients were randomly assigned to one of four treatment sequences at the end of the single-blind Circulation, Volume 51, June 1975 period, but dropouts produced unequal numbers in each group (see table 1 ).
Coded tablets were supplied which were identical in appearance and taste for the double-blind and run-in periods. Equivalence bioavailability of the active dose forms had been demonstrated previously (Caron and Davies, unpublished observations). Pulse and blood pressure were recorded by the nursing staff at each visit, and the numeric results of current and prior visits were not known to the doctors interviewing and examining the patients. Blood samples were obtained 90 to 180 min after the first morning dose during the fourth and sixth weeks of each dose period. Serum propranolol levels were measured using a modification of the fluorometric procedure of Shand et al. 5 Of the 21 patients entering the double-blind protocol, three were eliminated: one who died suddenly, one because of acute myocardial infarction, and a third who developed acute coronary insufficiency. Eighteen patients completed the double-blind portion of the study; however, one patient has been excluded from the data analysis because of the marked atypicality of his chest pain and inconsistency of his blood level measurements, suggesting failure to take medication. It was necessary to shorten five of the 68 double-blind periods completed by these 17 patients from six weeks to four weeks. One 80 mg double-blind period was shortened because of severe back pain unrelated to medication; one 160 mg dose period was shortened because of a missing bottle of medication; and three placebo periods were shortened because of severe angina. Following completion of the 24-week double-blind protocol, patients were given single-blind placebo tablets for an additional six weeks, during which time procedures were followed identical to those during the single-blind and double-blind protocols.
Exercise Testing
Exercise tolerance was measured by means of a symptomlimited exercise test performed between 15 and 45 min after the blood was sampled for serum propranolol levels. A multi-stage treadmill test was used, with a modification of the procedure of Bruce and Hornsten'0 to introduce two lesser exercise stages of 1 mph at 0% grade, and 1.2 mph at 5% grade. The speed and inclination of the treadmill were increased every three minutes. Prior to entry into the study, the initial exercise stage was selected for each patient such that angina developed more than three minutes after the start of exercise. Patients were instructed to stop walking at a similar level of pain for each test. ECG leads II and V5 were continuously monitored. Systolic blood pressure was measured at two-minute intervals and at exercise end point by external cuff techniques. The end point of exercise testing was chest pain for 16 patients and fatigue in one patient. Significant flat or downsloping ST-segment depression (0.1 mV for 0.08 sec) was exhibited by 11 patients, borderline ST-segment depression by four patients, and no ST-segment depression by two patients. The maximum heart rate at exercise end point ranged from 85 to 145 (mean 119), with ten patients limited at heart rates equal to or less than 115.
Statistical Analysis
A multivariate approach to statistical analysis was used, and the effect of time, which should be minimal due to the run-in period, was pooled into the over-all interaction. Carry-over effects from drug doses given in a preceding period were minimized by using only data from the last four weeks of each six-week period for analysis. In order to stabilize variance between patient groups (i.e., four treatment sequences), reduce the influence of a few large numbers (range of angina episodes/two weeks = 0-149, mean 15.9), and allow for the presence of zero angina episodes, a square root transformation was employed. Computational analysis was done using the Biomed Series Program X63. Two measures of clinical response to propranolol therapy were examined for statistical analysis: frequency of angina episodes, and nonprophylactic nitroglycerin consumption. Examination of run-in, single-blind placebo data, as shown in figure 1 , demonstrates that angina frequency and nitroglycerin consumption fell significantly (P < 0.05) within eight weeks of placebo therapy to two-thirds of their initial level, and then tended to stabilize over the succeeding four weeks. There was a substantial variability in individual patients from week to week, with some subjects exhibiting no placebo effect. A range of four to twelve weeks for stabilization to occur was noted. Figure 2 illustrates the results of angina frequency, and figure 3 the results of nitroglycerin consumption during the course of the study. Transformed square root data are plotted, and P values for statistical comparisons are shown. Both figures demonstrate a linear relationship betwen the logs of the three propranolol dosages and reduction of both angina frequency and nitroglycerin consumption.
Listed in table 3 are the degrees of freedom, F ratios and P values for comparisons between placebo periods and between placebo and propranolol drug periods. Also shown is the statistical analysis of groupto-group variation (interaction) associated with each main comparison between treatment periods. Since main effects are averages over the four different treatment sequences, the presence of interactions would U,) 3: The frequency of angina episodes and nonprophylactic nitroglycerin consumption is illustrated as a percentage of the initial two weeks for each two week segment of the twelve week duration of the single-blind run-in placebo period. Both indices of anginal severity fell within eight weeks of placebo therapy by one-third and tended to level off during the succeeding four weeks. (table 3A) are large enough to indicate that caution must be used in the interpretation of thecorresponding main effects. The cause of the interaction is the high level of symptoms in the double-blind placebo period for some patients. Figures 2 and 3 similarly emphasize that the levels of angina frequency and nitroglycerin consumption during double-blind placebo periods were more comparable to the levels of angina at the time of initial entry into the study than the level of angina at the end of the run-in period. For 13 of the 17 patients (groups B, C and D in table 1) the double-blind placebo period followed the therapeutically effective 160 mg dose. The results of angina frequency during the first and last four weeks of the placebo periods and the last four weeks of each of the doubleblind periods are shown as the square root of the number of angina episodes per two weeks. Frequency of angina episodes during the double-blind placebo period more closely approximated frequency upon initial entry into the study (first four weeks), than during the last four weeks of the single-blind placebo period. A linear relationship between the logs of the three propranolol dosages and reduction in angina frequency are exhibited. Statistical data, shown in the bottom half of the illustration, are obtained from table 3. These same patients (groups B, C and D) exhibited a significant difference (P < 0.05) between the doubleblind placebo period and the end of the run-in period (table 3A) . These facts suggest that patients, upon cessation of propranolol therapy, return to a level of angina similar to that experienced upon initial entry into the study, rather than back to the level attained after prolonged placebo therapy. Because of the differences between placebo periods and the possible presence of interactions, each of the propranolol dose periods has been compared with both the double-blind and the run-in placebo periods, the results of which are shown in table 3 (main comparisons) and figures 2 and 3. Comparisons of propranolol periods with double-blind placebo data t all dota averaged over last 4 weeks in eoch period P p<.05 * p<.OI Figure 3 The results of nonprophylactic nitroglycerin consumption are illustrated in the same manner as angina frequency in figure 2. Nitroglycerin consumption during the double-blind placebo period more closely approximated consumption upon initial entry into the study than during the last four weeks of the twelve week singleblind placebo period. A linear relationship between the log propranolol dosage and nitroglycerin consumption is exhibited. Statistical significances are illustrated in the lower half of the graph and appropriate F test statistics are listed in table 3. Circulation, Volume 51, June 1975 (2, 13 2.57 NS)* *Analysis of Groups B, C, and D only (i. e., includes only those patients for whom placebo followed the 160 mg dose).
Abbreviations: Plac = placebo; RI = run-in: SB = single-blind; DB = double-blind; First 4 = first 4 weeks; Last 4 = last 4 weeks; F = F statistic; DF = degrees of freedom; P = probability value; NS = not significant. statistically demonstrate propranolol efficacy for all three dose levels. This result is, however, favorably biased by the relative severity of symptoms during the double-blind control period. A more conservative comparison using placebo data at the end of the runin period documents propranolol's efficacy at the 160 mg (P < 0.07) and 320 mg (P < 0.05) dose levels.
At the end of each two-week visit, patients were asked to comment concerning the severity and duration of pain and how they felt in relation to the previous visit. Using subjective patient data, each double-blind period was assigned a global rating of excellent, good, fair or poor, which were assigned scores of 4, 3, 2 and 1, respectively. Figure 4 illustrates the number of patients in each clinical response category for placebo and the three propranolol dose periods. Although a favorable trend was observed for patients receiving 80 mg per day, only the 160 mg and 320 mg daily dosages achieved statistically significant results.
Using the criteria of 25% improvement of angina frequency compared to the last four weeks of the runin placebo period, six of 17 patients (35%) showed benefit at the 80 mg dose, ten of 17 patients (59%) showed benefit at the 160 mg dose, and 13 of 17 patients (76%) showed benefit at the 320 mg dose (table 4) .
For 11 of the 13 patients responding at the 320 mg dose, the increase from 160 mg to 320 mg improved angina suppression by an additional 14 to 53%. Four patients failed to demonstrate 25% or greater reduction in angina frequency at any propranolol dose when compared to run-in placebo data; however two individuals (patients 3 and 4) showed a dosecorrelated response compared to double-blind placebo values. The other two individuals had significant arteriographically-proven coronary disease and positive exercise tests. Although these four patients did not show significant suppression of angina episodes, all exhibited some clinical response based on strong dose-correlated changes in both physical activity and subjective ratings of the double-blind periods.
Exercise Tolerance
The results of exercise testing for each of the double-blind periods are summarized in figure 5 . The Circulation, Volume 51, June 1975 symptom limitation after exercise end point during the placebo double-blind period was pain for 16 of the 17 patients. With increasing doses of propranolol, exercise tolerance progressively lengthened from 325 sec to 410 sec, reaching statistical significance for the 320 mg dose period (P < 0.01). In addition, symptom limitation at exercise end point was shifted from pain to fatigue for seven of the 17 patients.
Listed in table 5 are the results of exercise-induced changes in heart rate, systolic blood pressure and the double product (systolic arterial pressure X heart rate). All three measures of propranolol effect were significantly suppressed at rest and at the exercise end point in a dose-related fashion. The increase in double-product with exercise from baseline was also attentuated progressively as the dose increased.
Correlation of Propranolol Serum Levels with Clinical Response and Degree of Beta-Blockade
Averages of two propranolol serum determinations, obtained during each of the 68 double-blind periods are listed in table 4 and shown in figure 6. The mean serum propranolol level was 24 ng/ml for the 80 mg/day dose, 67 ng/ml for the 160 mg/day dose and 173 ng/ml for the 320 mg/day dose. All determinations made during the placebo period yielded insignificant serum levels. A ten-fold range of serum levels was seen in different patients from an individual dose, and most patients exhibited a linear relationship between the log serum propranolol concentration and log dose. Individual patients were noted who had serum levels which were consistently in the upper or lower extremes for all doses. For each subject, the variation between samples taken on the fourth and sixth weeks of each double-blind period was small compared to the differences between results from the three propranolol dosages. Figure 7 illustrates the relation between individual clinical responses and log propranolol serum levels for those 13 individuals (patients 5 through 17, table 4) exhibiting a 25% or greater reduction in angina episodes at one or more propranolol doses (r = 0.52; P < 0.001). This figure shows that a serum level in excess of 30 ng/ml, when drawn 90 to 180 min following the last oral dose, was generally required to achieve 25% or greater reduction in angina frequency.
The degree of beta-adrenergic blockade for each propranolol dose was assessed during exercise testing by measuring the maximum heart rate at maximum exercise while patients were receiving placebo therapy. Heart rates were noted at the same levels of exercise during each of the three drug periods as had been maximally attained during placebo treatment. The measured heart rates were then recorded as a percentage of the placebo heart rate (table 4). Figure 8 illustrates the relationship between the i8  27  18  50  133  13  16  21   7  24  23  19  39  15  17  0  53  3  19  76  13  17  25  8  34  14   18  8  6  0  43  57  22  64  68  17  33  3,5  9  63   79   94   49  48  0  38  39   24  81  100  3  21  22   10  10  19  21  3  0  0  84  100  17  60  138  33  37  38  11  68  46  42  31  8  9  33  61  30  193  681  9  32  34  12  81  58  28  15   2  52  74  97  32  75  79  23  18  28  13  230  109  78  82  53  28  25  51  38  68  118  26  21   29  14  165  256  18a   172  120  28  33  53  61  140  334  21  30  26   15  7  7  4  1  0  43  86  100  30  53  207  24  37  34  16 30 29 degree of beta-blockade exhibited during exercise, the log propranolol serum levels, and the percent reduction in angina frequency for the same 13 patients whose data are illustrated in figure 7 . The correlation coefficient relating propranolol serum levels to the percent reduction in exercise heart rates was 0.51. In The time to exercise end point is illustrated for each of the doubleblind study periods. The duration of exercise tolerance increased significantly with the 320 mg propranolol dose compared to doubleblind placebo. Chest pain as an end point for exercise tolerance is illustrated by the solid circles and was present for 16 of 17 patients during placebo periods. Fatigue as an end point of exercise tolerance is illustrated by the open circles and at the highest propranolol dosage became the exercise limitation for eight of the 1 7 patients. addition, the data in this figure suggest that a serum propranolol level above 30 ng/ml or a heart rate reduction at equivalent levels of exercise of 20% or more yields a satisfactory clinical response. It appears that patients receiving lower propranolol dose levels who did not exhibit a 25% reduction in angina frequency are somewhat better discriminated by their inadequate degree of beta-blockade than by their propranolol serum level. Figure 9 confirms in these same 13 patients the relationship between the degree of beta-blockade measured by exercise heart rate reduction and the clinical response evaluated as reduction in angina frequency (r = 0.69). The relationship between propranolol dose, serum level, beta-blockade and clinical response is illustrated in figure 10 in the same manner as in figure 8 for three selected patients. Patient A (patient 7, table 4) exhibited a clinical response while receiving 320 mg per day; however this patient did not show a clinical response while receiving 80 or 160 mg doses. The data in figure 10 suggest that at both lower dosages, inadequate serum levels to produce significant reduction in exercise heart rate were attained. Three of the 13 who exhibited 25% or greater reductions in anginal frequency demonstrated this pattern (patients 5, 6 and 7). Patient B (patient 11, Every two weeks each patient was asked to volunteer drug side effects and was then specifically questioned concerning 20 possible adverse reactions. The most common responses were fatigue and lightheadedness, which occurred with sufficient frequency during both placebo and propranolol treatment periods to make these particular symptoms difficult to evaluate. Only those symptoms which could be directly attributable to propranolol administration during double-blind treatment periods, The log of the propranolol serum level attained 90 to 180 min after the last morning dose is plotted in ng/ml against the log of the daily propranolol dosage. A generally linear relationship was exhibited, with some patients exhibiting strikingly high or low serum level responses at the same oral dosage. per cent reduction in angina episodes compared to placebo run-in period Figure 7 The log of the propranolol serum level obtained 90 to 180 min after the first morning oral dosage is plotted against the percent reduction in angina episodes as compared to the placebo run-in period. Data for only those 13 patients who had a 25% or greater reduction in angina frequency at one or more dosages of propranolol are illustrated. In general, a serum level in excess of 30 ng/ml was required for significant clinical response. Percent reduction in angina episodes compared to placebo run -in period Figure 9 The percent reduction in exercise heart rate at the same exercise level is plotted against the percent reduction in angina episodes compared to the last four weeks of the placebo run-in period. A linear relationship is exhibited with a P value of 0.001. These data demonstrate the correlation between the degree of beta-blockade exerted by propranolol and its clinical effectiveness in reducing angina frequency (r = 0.68; y = 0.20 x + 15.7).
Percent reduction in excercise heart
rate at same exercise level Figure 8 The log of the propranolol serum level in ng/ml obtained 90 to 180 min following the last morning dose is plotted against the percentage reduction of exercise heart rate as measured at the same exercise level. Drug dosages which yielded less than 25% reduction in angina frequency generally were associated with serum levels below 50 ng/ml or less than 25% reduction in exercise heart rate. Patients exhibiting the most striking clinical responses (76 to 100% reduction in angina frequency) demonstrated 30% or greater reduction in exercise heart rate, with quite variable propranolol serum levels (r = 0.51; y = 14.1 e 056x) as compared to placebo periods, are listed in table 6. Adverse reactions were observed in seven of the 21 patients, including the 17 patients who completed the trial and the four patients who were treated for shorter periods. Drug-related side effects were mild, occurred generally in patients who had pre-existing symptoms and did not lead to drug cessation. Congestive heart failure was accentuated in two individuals, both of whom had pre-existing symptoms. Increased claudication was noted in two individuals, both of whom had pre-existing symptomatic peripheral vascular disease. Serum levels obtained during propranolol treatment periods, during which adverse reactions were noted, were in excess of 50 ng/ml for 12 of the 13 episodes.
Adverse reactions were not more common for those individuals who exhibited very high serum levels.
Comparison of angina frequency during run-in and double-blind placebo periods has already suggested that following discontinuation of propranolol patients return to the same level of angina which they had exhibited at the time of initial entry into the study. Four of the 13 patients who had abrupt transitions from the 160 mg daily propranolol dose to placebo experienced not only immediate return of angina, but also the onset of rest and nocturnal angina episodes (unstable angina) which had not previously been their pattern. One of these four patients developed frequent ven- The data on three selected patients are emphasize the relationship between prc degree of beta-blockade measured by the pi cise heart rate, the daily propranolol dosa, measured by percent reduction in angis Patient A typifies those individuals who j response while receiving 80 or 160 mg da adequate serum levels and inadequate d were achieved. Patient B typifies the indivi, clinical response while receiving 80 mg/c 160 mg or 320 mg/day achieved adequate quate degrees of beta-blockade. Some pati hibited responses at all three oral dosage effective degrees of beta-blockade we propranolol dosages. tricular premature beats, includ bigeminy, which were documen tape monitoring and disappeared reinstitution of propranolol therap unstable angina during place suddenly, and another patient in t: ting had a myocardial infarction. sisted in the fourth individual Circulation, Volume 51, June 1975 320 mg k 320 mg therapy was reinstituted. The only other major cardiovascular event during this study was acute coronary insufficiency, which occurred while the patient was receiving propranolol. A detailed description of these cases, along with three additional case reports, has been presented elsewhere. could be accomplished without experiencing significant angina. Increased physical activity carried over from the therapeutically effective 160 mg dose period into a placebo dose period could account for this adverse transition effect. In order to partially eliminate this carryover effect, only data from the last four weeks of each six-week period were employed. The data obtained during the 12-week placebo runin period pointed out that symptom reduction due to placebo effect was prominent for only the initial six to eight weeks. This is in contrast with earlier reports which suggested that an 11-week rapport period is necessary for stabilization.'7 The use of the last four weeks of the run-in placebo period as control data provided the most conservative estimate of propranolol efficacy.
The characterization of patients selected for participation in this study influences the extent to which extrapolations to the general population can be made. The requirement of five or more angina episodes per week at the end of a prolonged three-month placebo period strictly limited inclusion to those patients with stable, reproducible, severe angina and coronary artery disease. Fourteen of the 17 patients in our study had previously experienced myocardial infarctions, their first in all cases; however, only four had congestive heart failure, all well compensated. The data strongly suggest that patients with prior infarction but without uncompensated heart failure respond well to propranolol therapy.
The adverse reactions observed in this study were consistent in frequency and type with those observed in other studies.1' ' Severe angina symptoms occurring during placebo treatment periods following propranolol therapy have previously been observed by Mizgala15 and Zsoter.'6 The episodes of acute myocardial infarction and sudden death which we observed following abrupt propranolol cessation are similar to previous cases reported elsewhere.",16, [18] [19] [20] A wide range of serum levels was encountered between individual patients receiving the same dose. Shand5 noted a seven-fold range in peak plasma levels (36-212 ng/ml) following a single 80 mg oral dose. Zacest6 reports plasma levels ranging from 20 to 80 ng/ml following chronic daily dosages of 1.8 to 2.5 mg/kg (160 mg/day), a range which is similar to the 20 to 84 ng/ml range observed for most of our patients receiving similar dosages. Two individual patients exhibited strikingly high serum levels at all dosages of propranolol, the explanation for which may be a metabolic defect in the hydroxylation of propranolol as suggested by Zacest.6
The data from our study suggest that, for patients responsive to propranolol therapy, a threshold serum level in excess of 30 ng/ml is required for a clinical response. This clinical response is associated with a level of beta-adrenergic blockade which produces a 20% or greater reduction in the heart rate attained at the same exercise level reached at the point of symptom limitation without beta-blockade. The observed correlation between clinical response and pharmacologic effect as assessed by exercise testing was, in general, better than the correlation of clinical response with propranolol serum levels. The fact that serum levels were obtained at a time somewhat different from that of exercise testing (maximum 45 min) is probably not significant. Data from Evans and Shand21 suggest that for blood samples drawn 90 to 180 min following repeated oral doses, a variation of approximately 20% in plasma levels is found. This residual variability between serum levels and receptor effect is probably not due to the pharmacologic effects of an active metabolite, in view of the work of Cleaveland and Shand,22 which shows that the effect of chronic oral administration of propranolol can be attributed entirely to circulating levels of the parent drug. An additional explanation for this variability between clinical response and serum levels may be differences of propranolol kinetics between the intravascular compartment and the extravascular sites where the drug elicits its pharmacologic effect. Differences in propranolol distribution between body compartments has been suggested by analysis of propranolol data by Perrier and Gibaldi."
For most patients, little increase in beta-blockade was observed between the 160 mg and 320 mg daily dosages, suggesting that a relative maximum had been reached. Clinical response was, however, considerably enhanced at the higher dose, probably reflecting the fact that the degree of beta-blockade was assessed at a time of peak propranolol serum levels, whereas clinical response is assessed over a 4week interval. The propranolol serum level at the point of relative maximum beta-blockade was generally in excess of 50 ng/ml, which is consistent with the levels noted by Bodem et al.7 at the time of maximum reduction in exercise tachycardia. Coltart and Shand8 similarly observed plasma levels of 40 to 75 ng/ml at the time of maximum beta-blockade following single propranolol doses. Our data, therefore, suggest that substantial beta-blockade, as measured by exercise heart rate suppression, is required for a clinical response. Thus, the specific propranolol dosage required for successful therapy depends both on the blood drug level itself and upon the extent of beta-adrenergic blockade which results. the organizational and computational aspects of this study. We are appreciative of the outpatient nursing assistance provided by Mary Nivison and Amelia Turczinski, the comments provided by Dr.
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